Navigation Links
ViaCyte Announces Executive Management Changes
Date:8/9/2011

SAN DIEGO, Aug. 9, 2011 /PRNewswire/ -- ViaCyte, Inc. today announced changes to its  executive management team, including the appointment of Allan Robins, Ph.D., as Acting Chief Executive Officer, and the promotion of Kevin D'Amour, Ph.D., to Chief Scientific Officer.

Robins continues to serve as Vice President and Chief Technology Officer, and his appointment as acting CEO follows the departure of President and Chief Executive Officer John West who resigned for personal reasons. West continues his relationship with ViaCyte as a consultant and as a member of its Board of Directors. The Board has initiated a search for a new CEO.

"Allan has successfully led our process development and manufacturing operations since our merger with BresaGen in 2004 and has made a number of significant contributions to ViaCyte's research and technology platform.  We're pleased to have Allan assume this important interim CEO role. We also thank John West for his leadership and for his achievements in extending our company's funding resources," said Fred Middleton, Chairman of ViaCyte.

Prior to ViaCyte, Robins served as Chief Scientific Officer at BresaGen, Inc., the United States subsidiary of BresaGen Limited, an Australian biotechnology company that has since been acquired by Hospira, Inc.  Under Robins' leadership, BresaGen secured significant support from the National Institutes of Health for its stem cell research. Robins received his Ph.D. in molecular biology from the University of Adelaide in Australia and completed postdoctoral work at Cambridge University in England.

"I welcome the opportunity to serve in this expanded role as our forward progress continues," said Robins.  Commenting on D'Amour's promotion, Robins noted:

"Kevin has been essential in the development of our scientific program and is a world renowned stem cell expert.  As CSO, Kevin will lead the alignment of ViaCyte's research strategy with its business and operational goals, as well as publicly address the scientific aspects of the Company's technology platform."  

D'Amour joined ViaCyte in 2002 as a scientist and, along with his colleagues, authored four pivotal papers in Nature Biotechnology.  He is also the lead inventor of many of the Company's key patents, including those encompassing definitive endoderm and mesendoderm cells.  D'Amour earned his Ph.D. in biology at the University of California, San Diego.

"Our research team has worked tirelessly to position ViaCyte as the front runner in developing a cell therapy to treat diabetes," said D'Amour.  "I look forward to advancing our program to clinical trials."

About ViaCyte, Inc.

ViaCyte is a preclinical cell therapy company focused on diabetes. The Company's technology is based on pancreatic beta cell progenitors derived from human pluripotent stem cells. These cells are implanted using a durable and retrievable encapsulation device. Once implanted and matured, these cells secrete insulin in response to blood glucose levels. ViaCyte's goal is long term insulin independence without immune suppression, and without hypoglycemia and other diabetes-related complications.

ViaCyte is a private company headquartered in San Diego, California with additional operations in Athens, Georgia.  The Company is funded in part by the California Institute for Regenerative Medicine.

This news release may contain forward-looking statements made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995.


'/>"/>
SOURCE ViaCyte, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cellular Dynamics Licenses Technology From ViaCyte
2. NeoStem Announces the Receipt of Over $1,700,000 in DOD Funding for its VSEL™ Technology Being Developed to Treat Osteoporosis
3. Dendreon Announces Webcast Presentation at Canaccord Genuity Growth Conference
4. Osteologix Announces Completion of Corporate Consolidation
5. Interleukin Genetics, Inc. Announces Conference Call to Discuss Second Quarter 2011 Results
6. Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca
7. Rigel Announces Second Quarter 2011 Financial Results
8. WAVi Co. Announces Collaborative Agreement with SomaLogic, Inc.
9. Vermillion Announces Notice of Allowance for Peripheral Artery Disease (PAD) Patent
10. International Isotopes Inc. Announces Successful International Standards Certification for Manufacture of Its Nuclear Medicine Products and Devices
11. Biocept, Inc. Announces Availability of Its New Breast Cancer Test, OncoCEE-BR™ Utilizing Circulating Tumor Cells (CTCs)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 Houston Methodist Willowbrook Hospital ... Sports Association to serve as their official health ... Methodist Willowbrook will provide sponsorship support, athletic training ... association coaches, volunteers, athletes and families. ... Sports Association and to bring Houston Methodist quality ...
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, ... Pennsylvania Convention Center and will showcase its product’s latest features from June 26 ... presenting a scientific poster on Disrupting Clinical Trials in The Cloud during the ...
Breaking Biology Technology:
(Date:6/3/2016)... 2016 Das DOTM ... Nepal hat ein 44 Millionen ... Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an ... und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale ... teilgenommen, aber Decatur wurde als konformste und ...
(Date:5/24/2016)... 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology to ... display is the latest premium product recently added to the range of products distributed ... ... ... Imaging- LCD Medical Display- Ampronix News ...
(Date:5/3/2016)... Lithuania , May 3, 2016  Neurotechnology, ... released the MegaMatcher Automated Biometric Identification System ... of large-scale multi-biometric projects. MegaMatcher ABIS can process ... accuracy using any combination of fingerprint, face or ... MegaMatcher SDK and MegaMatcher Accelerator ...
Breaking Biology News(10 mins):